Completed PHASE3 INTERVENTIONAL 3-arm NCT00198107

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

Novel Pharmacological Strategies in Autism

Sponsor: Indiana University

Interventions Aripiprazole D-cycloserine Placebo

Updated 9 times since 2017 Last updated: Mar 29, 2019 Started: Sep 30, 2005 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00198107, this PHASE3 trial focuses on Autistic Disorder and remains completed. Sponsored by Indiana University, it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2019 — Jan 2021 [monthly]

Completed PHASE3
Apr 2019 — May 2019 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Apr 2019 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University
National Institute of Mental Health (NIMH)

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States